AI assistant
INOVIO PHARMACEUTICALS, INC. — Director's Dealing 2025
May 21, 2025
34008_dirs_2025-05-21_51fa4f8d-780e-4972-90c5-9d88de06bf4c.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: INOVIO PHARMACEUTICALS, INC. (INO)
CIK: 0001055726
Period of Report: 2025-05-20
Reporting Person: KIES PETER (CFO)
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2025-05-20 | Restricted Stock Unit | $ | A | 26100 | Acquired | Common Stock (26100) | Direct | |
| 2025-05-20 | Common Stock Option | $2.13 | A | 31950 | Acquired | 2035-05-20 | Common Stock (31950) | Direct |
Footnotes
F1: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 26,100 restricted stock units is as follows: 8,700 shares will vest on May 20, 2026; 8,700 shares will vest on May 20, 2027; 8,700 shares will vest on May 20, 2028. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both.
F2: The vesting schedule for the 31,950 options is as follows: 15,975 shares will vest on May 20, 2027 and 15,975 shares will vest on May 20, 2028.